Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy (iFOCUS)
Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy; the iFOCUS Study
Sponsor: UMC Utrecht
Listed as NCT06524570, this PHASE1 trial focuses on Cancer and Metastatic Cancer and remains actively recruiting participants. Sponsored by UMC Utrecht, it has been updated 4 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
4 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Feb 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jul 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UMC Utrecht
For direct contact, visit the study record on ClinicalTrials.gov .